Nuvation Bio Inc. (NUVB) NYSE

2.90

+0.16(+5.84%)

Updated at August 22 04:00PM

Currency In USD

Nuvation Bio Inc.

Address

1500 Broadway

New York City, NY 10036

United States of America

Phone

332 208 6102

Sector

Healthcare

Industry

Biotechnology

Employees

273

First IPO Date

August 26, 2020

Key Executives

NameTitlePayYear Born
Dr. David T. Hung M.D.Founder, President, Chief Executive Officer & Chairman1.2M1958
Dr. David C. Hanley Ph.D.Chief Technical Operations Officer586,0401970
Ms. Colleen SjogrenChief Commercial Officer615,8411971
Dr. David Liu M.D., Ph.D.Chief Medical Officer677,1511970
Dr. Gary Hattersley Ph.D.Chief Scientific Officer776,7601967
Ms. Kerry A. WentworthChief Regulatory Officer01973
Dr. Stephen Dang Ph.D.Senior Vice President, General Counsel & Corporate Secretary0N/A
Mr. Moses Makunje CPAVice President of Finance and Principal Accounting & Financial Officer01979
Ms. Stacy MarkelChief People Officer01965
Mr. Philippe SauvageChief Financial Officer & Principal Financial Officer01978

Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.